FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199054022> ?p ?o ?g. }

• W3199054022 abstract "INTRODUCTION: Erythropoiesis stimulating agents (ESA) are generally the first line of treatment of anaemia in lower risk myelodysplastic syndrome (MDS) patients. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective erythropoiesis including flow cytometry RED score, serum GDF-15, and hepcidin levels. METHODS: Inclusion criteria were: ESA naive, IPSS low or intermediate-1 MDS with Hemoglobin (Hb) level< 10g/dL. Patients received epoetin zeta 40 000 IU/week and erythroid response (HI-E, IWG 2006 criteria) was assessed at W12. sEPO level, iron parameters and hepcidin, flow cytometry (FC) Ogata and Red Score (RS), GDF-15, and molecular analysis by NGS were determined at baseline. RESULTS: 70 patients were included. Median age was 78 years. There were 22 RCMD, 19 RCUD, 14 RARS, 4 RAEB-1, 6 CMML, 2 del 5q-, 3 unclassifiable, R-IPSS was 13 very low, 47 low, 9 intermediate and high. Twenty patients were transfusion-dependent. HI-E was 48% and median duration of response was 26 months. At baseline, non-responders had significantly higher FC Red Score, lower hepcidin/ferritin ratio, lower IPSS.  In multivariate analysis, only RS>4 at T0 (p=0.05) and hepcidin/ferritin 2000 pg/ml and hepcidin/ferritin<9 (P=0.0008, and p=0.01, respectively). In multivariate analysis, both variables were associated with a shorter duration of response. CONCLUSION: Erythroid response to epoetin zeta was similar to that obtained with other ESAs. It was correlated with higher baseline hepcidin/ferritin ratio and lower Red score. Clinical Trial Number: Clinical trial Gov as NCT03598582. Funding Statement: This study received the support of a research grant from Hospira/Pfizer, the institutional support of Assistance Publique-Hopitaux de Paris through the Unite de Recherche Clinique Paris Descartes Necker Cochin. Declaration of Interests: Sophie Park has received research funding from Hospira/Pfizer. The remaining authors declare no competing financial interests. Ethic Approval Statement: All patients gave their written informed consent for biological investigations according to the recommendations of the local ethics committee (Comite de Protection des Personnes Paris V, CPP N° RCB 212-A01395-38, EUDRACT 2012-002990-7338) and the study was conducted in accordance with the Helsinki Declaration." @default.
• W3199054022 created "2021-09-27" @default.
• W3199054022 creator A5006532708 @default.
• W3199054022 creator A5013996935 @default.
• W3199054022 creator A5014838075 @default.
• W3199054022 creator A5015776056 @default.
• W3199054022 creator A5018074362 @default.
• W3199054022 creator A5018755298 @default.
• W3199054022 creator A5019257760 @default.
• W3199054022 creator A5019754040 @default.
• W3199054022 creator A5024027732 @default.
• W3199054022 creator A5025896775 @default.
• W3199054022 creator A5026119702 @default.
• W3199054022 creator A5031622487 @default.
• W3199054022 creator A5031776733 @default.
• W3199054022 creator A5032873950 @default.
• W3199054022 creator A5035332783 @default.
• W3199054022 creator A5036560089 @default.
• W3199054022 creator A5036907562 @default.
• W3199054022 creator A5037206907 @default.
• W3199054022 creator A5040576970 @default.
• W3199054022 creator A5046436694 @default.
• W3199054022 creator A5049643945 @default.
• W3199054022 creator A5053199721 @default.
• W3199054022 creator A5055166871 @default.
• W3199054022 creator A5055335263 @default.
• W3199054022 creator A5059641957 @default.
• W3199054022 creator A5061163564 @default.
• W3199054022 creator A5070246382 @default.
• W3199054022 creator A5070634987 @default.
• W3199054022 creator A5071847071 @default.
• W3199054022 creator A5072173051 @default.
• W3199054022 creator A5075558296 @default.
• W3199054022 creator A5075631269 @default.
• W3199054022 creator A5078864453 @default.
• W3199054022 creator A5079890028 @default.
• W3199054022 creator A5082195804 @default.
• W3199054022 creator A5084137235 @default.
• W3199054022 creator A5084651738 @default.
• W3199054022 creator A5090291825 @default.
• W3199054022 creator A5090679391 @default.
• W3199054022 date "2018-01-01" @default.
• W3199054022 modified "2023-10-12" @default.
• W3199054022 title "Dyserythropoiesis Evaluated by Red Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes" @default.
• W3199054022 doi "https://doi.org/10.2139/ssrn.3220773" @default.
• W3199054022 hasPublicationYear "2018" @default.
• W3199054022 type Work @default.
• W3199054022 sameAs 3199054022 @default.
• W3199054022 citedByCount "0" @default.
• W3199054022 crossrefType "journal-article" @default.
• W3199054022 hasAuthorship W3199054022A5006532708 @default.
• W3199054022 hasAuthorship W3199054022A5013996935 @default.
• W3199054022 hasAuthorship W3199054022A5014838075 @default.
• W3199054022 hasAuthorship W3199054022A5015776056 @default.
• W3199054022 hasAuthorship W3199054022A5018074362 @default.
• W3199054022 hasAuthorship W3199054022A5018755298 @default.
• W3199054022 hasAuthorship W3199054022A5019257760 @default.
• W3199054022 hasAuthorship W3199054022A5019754040 @default.
• W3199054022 hasAuthorship W3199054022A5024027732 @default.
• W3199054022 hasAuthorship W3199054022A5025896775 @default.
• W3199054022 hasAuthorship W3199054022A5026119702 @default.
• W3199054022 hasAuthorship W3199054022A5031622487 @default.
• W3199054022 hasAuthorship W3199054022A5031776733 @default.
• W3199054022 hasAuthorship W3199054022A5032873950 @default.
• W3199054022 hasAuthorship W3199054022A5035332783 @default.
• W3199054022 hasAuthorship W3199054022A5036560089 @default.
• W3199054022 hasAuthorship W3199054022A5036907562 @default.
• W3199054022 hasAuthorship W3199054022A5037206907 @default.
• W3199054022 hasAuthorship W3199054022A5040576970 @default.
• W3199054022 hasAuthorship W3199054022A5046436694 @default.
• W3199054022 hasAuthorship W3199054022A5049643945 @default.
• W3199054022 hasAuthorship W3199054022A5053199721 @default.
• W3199054022 hasAuthorship W3199054022A5055166871 @default.
• W3199054022 hasAuthorship W3199054022A5055335263 @default.
• W3199054022 hasAuthorship W3199054022A5059641957 @default.
• W3199054022 hasAuthorship W3199054022A5061163564 @default.
• W3199054022 hasAuthorship W3199054022A5070246382 @default.
• W3199054022 hasAuthorship W3199054022A5070634987 @default.
• W3199054022 hasAuthorship W3199054022A5071847071 @default.
• W3199054022 hasAuthorship W3199054022A5072173051 @default.
• W3199054022 hasAuthorship W3199054022A5075558296 @default.
• W3199054022 hasAuthorship W3199054022A5075631269 @default.
• W3199054022 hasAuthorship W3199054022A5078864453 @default.
• W3199054022 hasAuthorship W3199054022A5079890028 @default.
• W3199054022 hasAuthorship W3199054022A5082195804 @default.
• W3199054022 hasAuthorship W3199054022A5084137235 @default.
• W3199054022 hasAuthorship W3199054022A5084651738 @default.
• W3199054022 hasAuthorship W3199054022A5090291825 @default.
• W3199054022 hasAuthorship W3199054022A5090679391 @default.
• W3199054022 hasConcept C126322002 @default.
• W3199054022 hasConcept C2776768029 @default.
• W3199054022 hasConcept C2778248108 @default.
• W3199054022 hasConcept C2778319317 @default.
• W3199054022 hasConcept C2778534260 @default.
• W3199054022 hasConcept C2778917026 @default.
• W3199054022 hasConcept C2779703530 @default.
• W3199054022 hasConcept C2780007613 @default.
• W3199054022 hasConcept C2780817109 @default.
• W3199054022 hasConcept C71924100 @default.
• W3199054022 hasConcept C90924648 @default.

• next